This tetrafunctional antibody results in high tumour selectivity by targeting EGFR and the checkpoint inhibitor programmed death-ligand 1 (PD-L1) simultaneously, and has attenuated CD3ε binding, diminishing the cytokine release and toxicity effects. Here, EGFR is linked to neoplasm.